Bei Jing Shang Bao·2026-01-27 13:17Core Viewpoint - The company, CanSino (688185), is expected to achieve a net profit attributable to shareholders of between 24.5 million to 29 million yuan in 2025, marking a turnaround from losses in the previous year [1] Group 1: Financial Performance - The company anticipates a significant improvement in profitability, achieving a positive net profit for the reporting period [1] - The expected net profit range for 2025 represents a substantial recovery compared to the previous year's performance [1] Group 2: Strategic Initiatives - CanSino continues to focus on innovation and commercialization as key components of its development strategy [1] - The revenue from the first four-valent meningococcal vaccine, Manhaixin, is experiencing sustained growth [1] Group 3: Cost Management and Efficiency - The company has effectively controlled various expenses, contributing to improved overall profitability [1] - There has been an optimization in production and sales coordination, leading to an increase in gross margin [1] Group 4: Research and Development Support - The rapid advancement of the company's R&D projects and international collaborations has resulted in increased government grants and international funding [1] - The reporting period saw significant non-recurring income due to these additional financial supports [1]